ORIC Pharmaceuticals, Inc. — Form 8-K Summary
Reporting date: May 6, 2021. The filing reports the issuance of a press release announcing financial results for the fiscal quarter ended March 31, 2021.
Business Context and Reporting Period
ORIC Pharmaceuticals, Inc. is a Delaware biotechnology company with common stock listed on The Nasdaq Global Select Market under the symbol ORIC. The company identified itself as an emerging growth company and elected the extended transition period for new or revised accounting standards.
Financial Results and Liquidity
The filing references quarterly financial results but does not include the attached press release or provide clear values for revenue, net income or loss, cash flow, cash and equivalents, operating expenses, margins, debt, liquidity, or other financial metrics.
Changes Versus Prior Comparable Period
The filing text does not provide a clear comparison with the quarter ended March 31, 2020 or any other prior period.
Guidance, Outlook, Risks, and Unusual Items
No guidance, operating outlook, management commentary, risk updates, contingencies, or unusual items are described in the filing text. These matters may have been included in Exhibit 99.1, the May 6, 2021 press release, which is referenced but not reproduced in the provided content.
The financial-results information in Item 2.02 and Exhibit 99.1 was furnished rather than filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except through specific reference.
Important Facts to Verify
- Obtain and review Exhibit 99.1 for the actual March 31, 2021 financial results.
- Verify revenue, net loss, operating expenses, cash balance, cash burn, and remaining liquidity.
- Compare the reported results with the prior-year quarter and current analyst expectations, if applicable.
- Review any clinical, regulatory, financing, or development updates included in the press release.
- Confirm whether management provided updated cash-runway expectations or other forward-looking guidance.